• 
• 

Tuesday, November 26, 2024│11:15 a.m. - 12:15 p.m.

Hörsaal Fritz-Schumacher (building N30)

Dr. Miguel Ángel López-Unzu López and Laura Sen Martín, M.Sc. │ Spanish National Center for Cardiovascular Research (CNIC), Madrid

Host Prof. Dr. Lucie Carrier │ [email protected]

Lecture by Dr. Miguel Ángel López-Unzu López on
Titin cleavage as a driver of myocardial remodeling

Lecture by Laura Sen Martín, M.Sc. on
Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathy

• 
• 

Monday, November 25, 2024│5 - 6 p.m.

Hörsaal Fritz-Schumacher (building N30)

Prof. Dr. Corinna Brunckhorst, MD, FESC │ Professor of Cardiology and Co-Director of Electrophysiology at the University Heart Center, Zurich

Update on Arrhythmogenic Cardiomyopathies

Host Prof. Dr. Larissa Fabritz │ [email protected]

• 
• 

Monday, September 23, 2024│5 - 6 p.m.

Hörsaal Fritz-Schumacher (building N30)

Dr. David Filgueiras Rama │ Group Leader,
Spanish National Center for Cardiovascular
Research (CNIC), Madrid,
Cardiologist, Cardiac Electrophysiologist, Advanced Development in Arrhythmia Mechanisms
and Therapy Laboratory

Patient-specific characterization of atrial remodeling progression and wave propagation dynamics during atrial fibrillation

Hosts
Prof. Dr. Larissa Fabritz │ [email protected]
Dr. Laura Sommerfeld │ [email protected]

• 
• 

Thursday, July 11, 2024│5:30 - 6:30 p.m.

Hörsaal Fritz-Schumacher (building N30)

Prof. Dr. Sonja Schrepfer │ Professor at the
University of California San Francisco (UCSF),
Gladstone-UCSF Institute of Genomic Immunology, and
a Scientific Founder and SVP (Head of the Hypoimmune Platform) of Sana Biotechnology, Inc.

Host Prof. Dr. Viacheslav Nikolaev │ [email protected]

Introduction by
Prof. Dr. Dr. Hermann Reichenspurner │ University Heart & Vascular Center Hamburg (UHZ)

Protecting Allogeneic Transplants from Immune Rejection is the Key to Bringing Cell-based Therapies to Patients

In order to make allogeneic “off-the-shelf” cell therapies clinically useful and avoid rejection absent immunosuppression (IS), they need to evade host immune responses, a property we refer to as being “hypoimmune”. To overcome the allogeneic immune response, engineered cells must overcome both, adaptive and innate immunity. We demonstrated in various pre-clinical models using different cell types that protecting allogeneic transplants from rejection is feasible using genetic engineering to create hypoimmune cells.

• 
• 

Tuesday, July 9, 2024│5:00 - 6:00 p.m.

Hörsaal Fritz-Schumacher (building N30)

Dr. David Elliott │ Head of the Heart Disease Group at the Murdoch Children's Research Institute (MCRI),
Principal Investigator of the Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), and Member of the Melbourne Centre for Cardiovascular Genomics and Regenerative Medicine (CardioRegen)

Host Prof. Dr. Lucie Carrier │ [email protected]

Investigating genetic and acquired cardiomyopathy using human models

• 
• 

Monday, April 22, 2024│5 - 6 p.m.

Hörsaal Fritz-Schumacher (building N30)

Dr. Leif Hove-Madsen │Head of the
Cardiac Rhythm and Contraction Group,
Institute of Biomedical Research of Barcelona

Host Prof. Dr. Cristina Molina │ [email protected]

Genetic modulation of calcium homeostasis and electrical activity in human atrial myocytes

• 
• 

Monday, April 15, 2024│3:30 - 4:45 p.m.

Hörsaal Fritz-Schumacher (building N30)

Dr. Tim McKinsey │ School of Medicine,
Division of Cardiology, University of Colorado Denver

Regulation of Cardiometabolic Signaling by an Unusual Post-Translational Modification

Host Prof. Dr. Lucie Carrier │ [email protected]

• 
• 

Monday, February 26, 2024│5 - 6 p.m.

Hörsaal Frauenklinik (building W30)

Prof. Dr. Volker Spindler │ New Director of the Institute of Anatomy and Experimental Morphology / UKE

Breaking bad – Altered adhesion and Arrhythmogenic Cardiomyopathy

Host Prof. Dr. Larissa Fabritz │ [email protected]